Pharma Icebreaker Discussion: From Fear of Better to Fear of Missing Out, Pharma’s Strategic Priorities Across Neuroscience
- Comparing sentiment towards neuroscience deal-making, including: which stage of development is most appealing, which modalities are of interest, and what are the key elements of differentiation?
- Discussing data expectations to open a discussion. Guidance on data package and biomarker preferences seen as most credible or promising to generate interest for a deal decision
- Providing the best advice on what is expected when approaching any partner, understanding how to differentiate decks in crowded and sharing insights into types of interactions around early-stage and pre-IND